ABSTRACT
The efficacy and tolerability of risperidone long-acting injectable were investigated in patients with schizophrenia or other psychotic disorders who had previously been symptomatically stable on olanzapine treatment. Patients received risperidone long-acting injectable, 25 mg, by intramuscular injection every 2 weeks; the dose could be increased to 37.5 or 50 mg if necessary. Patients were transferred directly from their previous medication to risperidone long-acting injectable without a run-in period of oral risperidone treatment. Of 192 patients recruited, 134 patients (70%) completed the study. The principal reasons for discontinuation were withdrawal of consent (8%), adverse events (6%), insufficient response (5%) and non-compliance (4%). Risperidone long-acting injectable produced a significant improvement (p = 0.0001) in Positive and Negative Syndrome Scale (PANSS) total scores, from 74.2+/-21.3 at baseline to 65.8+/-21.4 at endpoint. There were also significant reductions in PANSS subscales (positive symptoms, negative symptoms, general psycho-pharmacology) and Marder factor scores. The Clinical Global Impression increased significantly from baseline to endpoint (p = 0.0001), as reflected by the increase in the proportion of patients rated as 'not ill' or 'borderline ill' from 10% at baseline to 21% at endpoint. Risperidone long-acting injectable was also associated with significant improvements in Global Assessment of Function, patient satisfaction with treatment, and quality of life, measured on the SF-36 scale. Movement disorders, measured on the Extrapyramidal Symptom Rating Scale, were significantly reduced following the change to risperidone long-acting injectable. Treatment with risperidone long-acting injectable was well tolerated, and no significant weight gain occurred during the study. This open study suggests that risperidone long-acting injectable produces symptomatic improvement in schizophrenia patients previously considered symptomatically stable with olanzapine, along with improvement in movement disorders. The combination of improved efficacy and good tolerability may have important implications for patient adherence to therapy and subsequent long-term outcomes.
Subject(s)
Antipsychotic Agents/therapeutic use , Psychotic Disorders/drug therapy , Risperidone/therapeutic use , Adult , Antipsychotic Agents/administration & dosage , Antipsychotic Agents/adverse effects , Benzodiazepines/adverse effects , Benzodiazepines/therapeutic use , Body Mass Index , Body Weight/drug effects , Delayed-Action Preparations , Dyskinesia, Drug-Induced/epidemiology , Female , Humans , Male , Middle Aged , Olanzapine , Prospective Studies , Psychiatric Status Rating Scales , Psychotic Disorders/psychology , Quality of Life , Risperidone/administration & dosage , Risperidone/adverse effects , Treatment OutcomeABSTRACT
Use and interest of therapeutic association bromocriptine-neuroleptic in schizophrenia. Twelve schizophrenic patients were treated by bromocriptine (7.5 mg.day) and neuroleptic. After one month, patients on this treatment showed a mean improvement of 29% on the total score of the positive and negative symptom scale. This results suggest that therapeutic association bromocriptine-neuroleptic may be used for schizophrenic patients.
Subject(s)
Antipsychotic Agents/therapeutic use , Bromocriptine/therapeutic use , Dopamine Agonists/therapeutic use , Schizophrenia/drug therapy , Adult , Antipsychotic Agents/adverse effects , Drug Therapy, Combination , Dyskinesia, Drug-Induced/drug therapy , Dyskinesia, Drug-Induced/etiology , Humans , Hyperprolactinemia/chemically induced , Hyperprolactinemia/drug therapy , Middle Aged , Psychiatric Status Rating Scales , Treatment OutcomeABSTRACT
The authors, taking up their experience and the literature, attempt to view the precociousness of alternative, classical neuroleptic treatments in schizophrenia, from notion of treatment-resistant schizophrenia, precocious refractory and intolerance. Until now, clozapine was administrated to patients lasting resistant and in mainly cases hospitalized since many years. As such as quality of life and economy of health, it would be desirable to quickly think of alternatives neuroleptic's therapeutic protocols and clozapine in the treatment-resistant schizophrenias or those presenting an intolerance.
Subject(s)
Antipsychotic Agents/administration & dosage , Schizophrenia/drug therapy , Schizophrenic Psychology , Adult , Antipsychotic Agents/adverse effects , Drug Administration Schedule , Female , Humans , Male , Prognosis , Psychiatric Status Rating ScalesABSTRACT
Starting from a study of memory performances while prescription in double blind of lorazepam (2 mg/day) versus tiapride (100 mg/day), during ten days, to patients over sixty years of age, the authors try to analyse the links between anxiety, anxiolysis and attention and memory capacities. Results seem to indicate that beyond anxiolysis, these products could have an independent action over memory performances. Statistical trial of results show significantly that performances decrease under lorazepam and increase under tiapride.
Subject(s)
Aging , Benzamides/pharmacology , Lorazepam/adverse effects , Memory/drug effects , Tiapamil Hydrochloride/pharmacology , Aged , Arousal/drug effects , Attention/drug effects , Double-Blind Method , Humans , Memory Disorders/chemically inducedABSTRACT
The authors' purpose was to confirm their hypotheses based on their prior study of the effect of tiapride and lorazepam on memorizing capacities of patients over sixty years of age. The results of a two weeks, double-blind trial show that tiapride, in addition to its sedative action, produces disinhibition and enhances wakefulness, thereby improving memory performances in the elderly.
